Allogene Therapeutics, Inc.

ALLO

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0002057918-26-000003
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026

Summary

Type

Sell

Net shares

-7,132

% of shares

-3.39%

Amount (USD)

$18,543

Insider confidence score

46.3 out of 100

Positive

  • Tax withholding obligation
  • Small sell amount (<$50K)

Negative

  • Large tax withholding sell (≥1% of shares)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-7,132.0

Price per Share

$2.60

Amount (USD)

$18,543.20

Acquired/Disposed

Disposed

Shares Owned Before

210,172.0

Shares Owned After

203,040.0

Filing's footnotes

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's electionunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a &quot;sell to cover&quot; transaction and does not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.67, inclusive. The reporting person undertakes toprovide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate pricewithin the range set forth above.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.